European Shorting
| New Threads Only: |  |  |  |
|
|---|---|---|---|---|
| New Threads & Replies: | | | |
|
Forum List » Business News and Headlines SEC Filings, Earing Reports, Press Releases  
Halozyme Therapeutics Inc. Reports Operating Results (10-Q)
Posted by: gurufocus (IP Logged)
Date: August 7, 2009 07:19AM
Halozyme Therapeutics Inc. (HALO) filed Quarterly Report for the period ended 2009-06-30. Highlight of Business Operations:In November 2008, we filed a shelf registration statement on Form S-3 (Registration No. 333-155787) which allowed us, from time to time, to offer and sell up to $50.0 million of equity or debt securities. In June 2009, we sold approximately $40.0 million of our common stock in a public offering at a price of $6.50 per share. We may utilize this universal shelf in the future to raise capital to fund the continued development of our product candidates, the commercialization of our products or for other general corporate purposes. Revenues Under Collaborative Agreements — Revenues under collaborative agreements were approximately $1.2 million for the three months ended June 30, 2009 compared to $1.4 million for the three months ended June 30, 2008. Revenues under collaborative agreements primarily consisted of the amortization of license fees received from Baxter and Roche of approximately $756,000 and $588,000 for the three months ended June 30, 2009 and 2008, respectively. Revenues under collaborative agreements also included reimbursements for research and development services from Baxter of $276,000 and $554,000 and Roche of $214,000 and $210,000 for the three months ended June 30, 2009 and 2008, respectively. Such reimbursements are for research and development services rendered by us at the request of Baxter and Roche and the amount of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to increase in future periods provided that we meet various clinical and regulatory milestones set forth in such agreements. Research and Development — Research and development expenses were $14.6 million for the three months ended June 30, 2009 compared to $8.9 million for the three months ended June 30, 2008. The increase of $5.7 million, or 64%, was primarily due to the increase in clinical trial expenses of $2.0 million, outsourced research and development costs of $1.9 million related to our various preclinical programs and the manufacturing scale-up of our rHuPH20 enzyme, and increased compensation costs of $1.5 million, of which $160,000 related to increased share-based compensation, primarily due to the increase in our research and development headcount. At June 30, 2009, our headcount for research and development functions totaled 98 employees, compared with 83 employees at June 30, 2008. We expect certain research and development costs to increase in future periods as we increase our research efforts, expand our clinical trials and continue to develop and manufacture our product candidates. Net Loss — Net loss was $17.1 million, or $0.21 per common share, for the three months ended June 30, 2009 compared to $11.0 million, or $0.14 per common share for the three months ended June 30, 2008. The increase in net loss was primarily due to an increase in operating expenses. Revenues Under Collaborative Agreements — Revenues under collaborative agreements were approximately $3.9 million for the six months ended June 30, 2009 compared to $3.0 million for the six months ended June 30, 2008. Revenues under collaborative agreements primarily consisted of the amortization of license fees and milestone payments received from Baxter and Roche of approximately $2.5 million and $1.2 million for the six months ended June 30, 2009 and 2008, respectively. Revenues under collaborative agreements also included reimbursements for research and development services from Baxter of $700,000 and $1.0 million and Roche of $744,000 and $834,000 for the six months ended June 30, 2009 and 2008, respectively. Such reimbursements are for research and development services rendered by us at the request of Baxter and Roche and the amount of future revenues related to reimbursable research and development services is uncertain. We expect the non-reimbursement revenues under our collaborative agreements to continue to increase in future periods provided that we meet various clinical and regulatory milestones set forth in such agreements. Research and Development — Research and development expenses were $28.6 million for the six months ended June 30, 2009 compared to $17.4 million for the six months ended June 30, 2008. The increase of $11.2 million, or 64%, was primarily due to the increase in outsourced research and development costs of $4.5 million related to our various preclinical programs and the manufacturing scale-up of our rHuPH20 enzyme, and increased compensation costs of $3.2 million, of which $357,000 related to increased share-based compensation, primarily due to the increase in our research and development headcount. At June 30, 2009, our headcount for research and development functions totaled 98 employees, compared with 83 employees at June 30, 2008. Additionally, our clinical
Sorry, only registered users may post in this forum.
Please Login if you have an account or Create a Free Account if you don't 
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names 
|
Feedback
My Portfolios
Browse Gurus
RSS